CapsoVision Announces Closing of Initial Public Offering

Core Viewpoint - CapsoVision, Inc. has successfully completed its initial public offering (IPO) of 5,500,000 shares at a price of $5.00 per share, raising gross proceeds of $27.5 million before expenses [1][2]. Company Overview - CapsoVision is a commercial-stage medical technology company focused on advanced imaging and AI technologies for capsule endoscopy solutions [1][4]. - The flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that provides high-resolution visualization of the small bowel [4]. - The company is developing a pipeline product, CapsoCam Colon, aimed at non-invasive colon imaging and polyp detection, with plans to expand across multiple gastrointestinal indications [4]. IPO Details - The shares began trading on the Nasdaq Capital Market under the ticker symbol "CV" on July 2, 2025 [1]. - The underwriters have a 30-day option to purchase an additional 825,000 shares at the IPO price [1]. - The offering was managed by The Benchmark Company, LLC and Roth Capital Partners [2]. Regulatory Information - A registration statement on Form S-1 was declared effective by the U.S. Securities and Exchange Commission (SEC) on July 1, 2025, allowing the offering to proceed [3].